PL2205279T3 - Farmaceutyczna kombinacja aliskirenu i walsartanu - Google Patents

Farmaceutyczna kombinacja aliskirenu i walsartanu

Info

Publication number
PL2205279T3
PL2205279T3 PL08835893T PL08835893T PL2205279T3 PL 2205279 T3 PL2205279 T3 PL 2205279T3 PL 08835893 T PL08835893 T PL 08835893T PL 08835893 T PL08835893 T PL 08835893T PL 2205279 T3 PL2205279 T3 PL 2205279T3
Authority
PL
Poland
Prior art keywords
aliskiren
valsartan
minutes
dose combination
fixed dose
Prior art date
Application number
PL08835893T
Other languages
English (en)
Inventor
Catherine Curdy
Shoufeng Li
Dieter Becker
Burkhard Schlütermann
Frédéric Gerber
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2205279T3 publication Critical patent/PL2205279T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL08835893T 2007-09-28 2008-09-24 Farmaceutyczna kombinacja aliskirenu i walsartanu PL2205279T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97590507P 2007-09-28 2007-09-28
EP08835893A EP2205279B1 (en) 2007-09-28 2008-09-24 Pharmaceutical combination of aliskiren and valsartan
PCT/US2008/077417 WO2009045796A1 (en) 2007-09-28 2008-09-24 Pharmaceutical combination of aliskiren and valsartan

Publications (1)

Publication Number Publication Date
PL2205279T3 true PL2205279T3 (pl) 2011-09-30

Family

ID=40394241

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08835893T PL2205279T3 (pl) 2007-09-28 2008-09-24 Farmaceutyczna kombinacja aliskirenu i walsartanu

Country Status (16)

Country Link
US (1) US20100247645A1 (pl)
EP (1) EP2205279B1 (pl)
JP (1) JP2010540548A (pl)
KR (1) KR20100059912A (pl)
CN (1) CN101808665A (pl)
AT (1) ATE505203T1 (pl)
AU (1) AU2008309059A1 (pl)
BR (1) BRPI0817275A2 (pl)
CA (1) CA2697437A1 (pl)
DE (1) DE602008006243D1 (pl)
ES (1) ES2364538T3 (pl)
MX (1) MX2010003439A (pl)
PL (1) PL2205279T3 (pl)
PT (1) PT2205279E (pl)
RU (1) RU2010116526A (pl)
WO (1) WO2009045796A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI468191B (zh) * 2009-01-28 2015-01-11 Novartis Ag 有機化合物之調配物
US20120009257A1 (en) * 2009-03-20 2012-01-12 Indrajit Ghosh Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren
AR080683A1 (es) * 2010-03-16 2012-05-02 Novartis Ag Composiciones farmaceuticas de aliskiren y metodos de administracion
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
RU2671575C2 (ru) 2011-05-10 2018-11-02 Теравида, Инк. Применение солифенацина и стимуляторов слюноотделения в лечении гиперактивного мочевого пузыря
CN102247344A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血压组合物
CN102626395B (zh) * 2012-04-19 2014-02-26 海南美兰史克制药有限公司 一种阿利克仑缬沙坦药物组合物脂质体固体制剂
US10376470B2 (en) * 2012-05-01 2019-08-13 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
PT2844233T (pt) * 2012-05-01 2020-06-25 Althera Life Sciences Llc Formulação de comprimido oral que consiste numa combinação fixa de rosuvastatina e ezetimiba para o tratamento de hiperlipidemia e doenças cardiovasculares
WO2013166114A1 (en) * 2012-05-01 2013-11-07 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe
WO2017127073A1 (en) 2016-01-20 2017-07-27 Theravida, Inc. Methods and compositions for treating hyperhidrosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
MY144477A (en) * 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds
ATE551052T1 (de) * 2004-10-08 2012-04-15 Novartis Ag Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
KR20080005926A (ko) * 2005-03-22 2008-01-15 노파르티스 아게 항고혈압제로서 알리스키렌의 효능에 대한 바이오마커
KR101384841B1 (ko) * 2005-06-27 2014-04-15 다이이찌 산쿄 가부시키가이샤 안지오텐신 ⅱ 수용체 길항제 및 칼슘 채널 차단제를함유한 약학 제제

Also Published As

Publication number Publication date
DE602008006243D1 (de) 2011-05-26
AU2008309059A1 (en) 2009-04-09
EP2205279A1 (en) 2010-07-14
CA2697437A1 (en) 2009-04-09
ATE505203T1 (de) 2011-04-15
US20100247645A1 (en) 2010-09-30
CN101808665A (zh) 2010-08-18
BRPI0817275A2 (pt) 2015-06-16
JP2010540548A (ja) 2010-12-24
RU2010116526A (ru) 2011-11-10
ES2364538T3 (es) 2011-09-06
MX2010003439A (es) 2010-04-21
PT2205279E (pt) 2011-07-11
KR20100059912A (ko) 2010-06-04
WO2009045796A1 (en) 2009-04-09
EP2205279B1 (en) 2011-04-13

Similar Documents

Publication Publication Date Title
MX2010003439A (es) Combinacion farmaceutica de aliskiren y valsartan.
TN2010000135A1 (en) Galenical formulations of organic compounds
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
GB0618879D0 (en) Pharmaceutical compositions
UA92641C2 (ru) Комбинированная препаративная форма, которая содержит амлодипин и лозартан
MX347106B (es) Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
MX2010004323A (es) Formas de dosificacion oral que comprenden acetato de licarbazepina.
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
NZ628513A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
HRP20041092A2 (en) New pharmaceutical compositions containing filbanserin polymorph a
WO2008003050A3 (en) Gallium nitrate formulations
IL187632A (en) 17 – Ethinyl – 17 – Hydroxy – 13 – Methyl – 17,16,15,14,13,12,11,9,8,7 – Dachahydro – 6 h– Cyclopentane [a] Penanthran – 3 – Ilmethyl ester of acetoxy acid Acetic, a pharmaceutical dosage unit containing it and its use in the preparation of a contraceptive
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases
ME01402B (me) Postupak sinteze derivata 1.3-dihidro-2h-3-benzazepin-2-on-a i primena u sintezi ivabradina i adicionih soli farmaceutski prihvatljive kiseliine
JO3239B1 (ar) تركيبات جالينية من مركبات عضوية
UA102111C2 (uk) Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.
TN2011000100A1 (en) Galenical formulations of organic compounds
MX2011009846A (es) Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno.
TW200833375A (en) Pharmaceutical compositions
PL1817029T3 (pl) Pochodna izoksazolowa do łagodzenia bólu neuropatycznego